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Abstract
Accurate determination of the presence and degree 
of fibrosis in liver is of great importance, because the 
prognosis and management strategies for chronic liver 
disease depend mainly on these factors. To date, liver 
biopsy (LB) remains the “gold standard” for assess-
ing the severity of liver fibrosis; however, LB is often 
limited by its invasiveness, sampling error, and intra/
inter-observer variability in histological interpretation. 
Furthermore, repeated LB examinations within a short 
time interval are indeed ineligible in a real clinical prac-
tice. Thus, due to the pressing need for non-invasive 
surrogates for liver fibrosis, transient elastography (TE), 
as a novel ultrasound based technology, has allowed 
a noninvasive measurement of liver stiffness and has 
gained in popularity over recent years. In the past 
few years, additional roles for transient TE beyond the 
initial purpose of a non-invasive surrogate for LB have 
included the prediction of the most two critical conse-
quences of fibrosis progression: the development of 
portal hypertension-related complications and hepato-
cellular carcinoma. This indicates that the role of tran-
sient TE is not merely limited to reducing the need for 
LB, but transient TE can enable the establishment of 
tailored management strategies by providing more de-
tailed prognostic information. In particular, under the 
concept in which the clinical course of liver fibrosis is 
dynamic and bidirectional, especially when appropriate 
intervention is commenced, transient TE can be used 
to track the dynamic changes in fibrotic burden during 
antiviral or antifibrotic treatment. This review discus-
sed extended applications of transient TE in prediction 
of the development of real clinical endpoints from a 
longitudinal perspective.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
The prognosis and management of  chronic liver disease 
(CLD) depend mainly on the amount and progression 
REVIEW
Online Submissions: http://www.wjgnet.com/esps/
wjg@wjgnet.com
doi:10.3748/wjg.v19.i12.1890
1890 March 28, 2013|Volume 19|Issue 12|WJG|www.wjgnet.com
World J Gastroenterol  2013 March 28; 19(12): 1890-1900
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2013 Baishideng. All rights reserved.
of  liver fibrosis, which is defined as the excessive accu-
mulation of  extracellular matrix proteins, resulting from 
chronic liver insults[1,2]. The initiation of  its deposition is 
an important phase of  CLD. As liver fibrosis eventually 
progresses without appropriate intervention, this process 
will lead to architectural change of  the liver, followed by 
deterioration of  liver function and hemodynamics, com-
plications due to portal hypertension, and an increased 
tendency for hepatocarcinogenesis[3].
Thus, accurate determination of  the presence and de-
gree of  liver fibrosis is of  paramount importance in choos-
ing treatment strategies, evaluating responses to treatment 
and the risks of  developing liver-related complications, and 
predicting prognosis in patients with CLD. To assess the 
severity of  liver fibrosis, liver biopsy (LB) remains the “gold 
standard”. However, LB is often limited by its invasiveness 
and rare, but serious, complications, including bleeding, 
pneumothorax, and procedure-related death[4,5]. Moreover, 
repeated LB examinations within a short time interval 
are impractical. Additionally, concerning the reliability of  
pathological examinations, not only sampling error inher-
ent in the percutaneous approach, but also intra- and inter-
observer variability in histological interpretation may still 
occur[6]. Even if  the LB is performed by an experienced 
physician and interpreted by an expert pathologist, it has 
an up to 20% error rate in disease staging[7,8].
Ideally, a method of  evaluating liver fibrosis should 
accurately determine the presence of  significant fibrosis, 
and be readily available, highly reproducible, and widely 
applicable to liver diseases of  various etiologies. Although 
LB does not fulfil all these criteria, it has remained the 
gold standard, likely due to the absence of  a better alter-
native. Recently, liver stiffness measurement using tran-
sient elastography (TE) was introduced as a promising 
non-invasive method for assessment of  liver fibrosis[9-15]. 
In many studies, TE proved to be a reliable and accurate 
surrogate for LB in terms of  prediction of  significant 
fibrosis or cirrhosis[8,16-19]. In a large-scale meta-analysis 
including 50 studies, the mean areas under the receiver 
operating characteristic curves (AUROCs) for the diagno-
sis of  significant fibrosis and cirrhosis were 0.84 and 0.94, 
respectively, with optimal cutoff  values of  7.6 and 13.1 
kPa, respectively[20].
Most studies to date have focused on assessing the 
performance of  TE, reflected by AUROC, from a cross-
sectional perspective, with reference to histological fi-
brosis. However, because LB as a reference standard is 
imperfect, it may have only limited clinical implications in 
terms of  increasing the AUROC of  TE to 1 (i.e., perfect 
concordance with LB). Thus, additional roles for TE, 
namely prediction of  long-term prognosis of  the disease 
and monitoring clinical courses, have recently begun to 
attract attention. This indicates that the role of  TE is not 
merely limited to lessening the frequency of  unnecessary 
LB, but TE can also enable establishment of  tailored 
management strategies by providing more detailed prog-
nostic information[21]. In this regard, the “classical” end-
points of  “static” liver fibrosis in recent cross-sectional 
studies on TE are shifting to the “real and solid” end-
points of  the development of  clinical events related to 
liver fibrosis progression, including hepatic decompensa-
tion, hepatocellular carcinoma (HCC), or liver-related 
death in a longitudinal study from a prospective cohort 
with long-term follow-up. Additionally, the performance 
of  non-invasive methods is being judged and compared 
from this viewpoint.
In this article, we reviewed recent studies that focused 
on the prognostic value of  TE for prediction of  clini-
cal end-points related to liver fibrosis progression, such 
as decompensation events, HCC development, or liver-
related death, from a longitudinal perspective.
PREDICTION OF THE DEVELOPMENT OF 
LIVER-RELATED COMPLICATIONS
Portal hypertension-related complications
The development of  portal hypertension is a common 
consequence of  fibrosis progression, leading to the for-
mation of  esophageal and gastric varices responsible for 
variceal bleeding, and other severe complications, such 
as portosystemic encephalopathy, spontaneous bacterial 
peritonitis and sepsis[22-24]. Measurement of  the hepatic 
venous pressure gradient (HVPG) is the gold standard 
for portal hypertension assessment in patients with cir-
rhosis; however, it is invasive and is routinely available 
only in experienced centers[25-29]. Although TE was initially 
proposed for assessment of  liver fibrosis, a good correla-
tion between TE values and HVPG has been reported, as 
well as the presence of  esophageal varices, suggesting that 
it may be a valuable tool for the non-invasive evaluation 
of  portal hypertension[30-32]. Subsequent studies have in-
vestigated correlations between TE values and the hepatic 
decompensation due to increased portal hypertension. A 
significant correlation between TE values and portal hy-
pertension, expressed as the HVPG, was reported by Viz-
zutti et al[33] suggesting that TE may reflect a progressive 
rise in portal pressure due primarily to increased hepatic 
vascular resistance, caused by fibrillar extracellular matrix 
accumulation. Based on this concept, Foucher et al[34] first 
reported that cutoff  values of  27.5, 37.5, 49.1, 53.7 and 
62.7 kPa had > 90% negative predictive values for the 
presence of  large esophageal varices (stage 2/3), Child-
Pugh score B or C, past history of  ascites, HCC and 
esophageal bleeding, respectively.
As variceal bleeding is a life-threatening complica-
tion of  portal hypertension, the relationship between TE 
values and the presence of  esophageal varices has been 
investigated in several studies[35-40]. All demonstrated a sig-
nificant correlation between TE values and the presence 
of  esophageal varices and that TE values could predict 
the presence of  large varices (more than grade 2)[38,40]. 
Table 1 summarizes reports of  the relationship between 
TE values and esophageal varices[33,38,40-44].
Although TE can predict the presence of  esophageal 
varices and consequently assist in selection of  candidates 
for endoscopic screening or prophylactic treatment, sever-
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al issues remain unresolved. First, the cutoff  values (range, 
13.9-21.5 kPa) and performance of  TE varied (AUROC 
range, 0.76-0.85) among studies[38-40]. Second, from data 
currently available, diagnostic performances of  TE are 
acceptable for the prediction of  esophageal varices, but 
far from satisfactory for screening cirrhotic patients with-
out endoscopy confidently. Thus, Kim et al[45] recently 
proposed a novel prediction model [liver stiffness-spleen 
diameter to platelet ratio score (LSPS)] to address this is-
sue, achieving higher accuracy using TE values and other 
parameters simultaneously that reflect portal hyperten-
sion as constituent variables. Overall, this model had 
excellent diagnostic accuracy for the prediction of  high-
risk esophageal varices (HEV, AUROC = 0.953; negative 
predictive value 94.7%, positive predictive value 93.3%).
Beyond this cross-sectional analysis, a subsequent 
study by the same group recently showed that LSPS can 
be a reliable predictor of  the development of  variceal 
bleeding[20]. In this prospective, longitudinal study analyz-
ing 577 patients with hepatitis B virus-related cirrhosis, 
those with LSPS ≥ 5.5 had higher cumulative incidences 
of  esophageal variceal bleeding during the follow-up pe-
riod and LSPS score ≥ 6.5 was an independent risk factor 
of  variceal bleeding among those with HEV, indicating 
that further prophylactic treatment such as endoscopic 
ligation in addition to a non-selective beta-blocker should 
be considered in these high-risk patients (Figure 1). In a 
similar context, Kim et al[46] stratified the risk of  hepatic 
decompensation, such as ascites, hepatic encephalopathy, 
variceal hemorrhage, and deterioration of  liver function to 
Child-Pugh class B or C, based upon three classes of  TE 
values (TE value < 13, 13-18 and ≥ 18 kPa) in histologi-
cally proven hepatitis B virus-related cirrhosis with well-
preserved liver function and no history of  decompensa-
tion. In a multivariate analysis, patients with a TE value of  
13-18 kPa [hazard ratio (HR), 4.547; P = 0.044] and ≥ 18 
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  Ref. No. of patients (etiology) Endpoints AUROC Cutoffs (kPa) Sensitivity Specificity PPV NPV
  Vizzutti et al[33]   47 (HCV) EV 0.76 17.6 90% 43% 77% 66%
  Castéra et al[38]   70 (HCV) EV 0.84 21.5 76% 78% 68% 84%
Large EV 0.87 30.5 77% 85% 56% 94%
  Kazemi et al[40] 165 (CLD) EV 0.83 13.9 95% 43% 57% 91%
Large EV 0.84 19.0 91% 60% 48% 95%
  Bureau et al[41]   89 (CLD) EV 0.85 21.1 84% 71% NA
NA
NA
NALarge EV 0.76 29.3 81% 61%
  Pritchett et al[42] 211 (CLD) EV 0.74 19.5 76% 66% 56% 82%
Large EV 0.76 19.8 91% 56% 91% 55%
  Nguyen-Khac et al[43] 183 (CLD) Large EV 0.76 48.0 73% 73% 44% 90%
              58 (HCV/HBV) Large EV 0.73 19.8 89% 55% 27% 97%
     103 (alcohol) Large EV 0.77 47.2 85% 64% 44% 93%
  Malik et al[44] 124 (CLD) EV 0.85 20.0 NA NA 80% 75%
Table 1  Diagnostic performance of transient elastography for prediction of esophageal varices or large esophageal varices
AUROC: Area under the receiver operating characteristic curve; PPV: Positive predictive value; NPV: Negative predictive value; CLD: Chronic liver 
disease; EV: Esophageal varix; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NA: Not available.
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Figure 1  Cumulative incidences of variceal bleeding based on liver stiffness-spleen diameter to platelet ratio score values. A: The incidence of variceal 
bleeding increased significantly in association with higher liver stiffness-spleen diameter to platelet ratio score (LSPS) values (long-rank test, P < 0.001); B: In particu-
lar, among patients with high risk esophageal varices (EV), the incidence of variceal bleeding was significantly higher in patient with LSPS 6.5 (subgroup 2) than those 
with LSPS < 6.5 (subgroup 1). 
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clinical role of  TE in the noninvasive prediction of  HCC 
development[52-56]. The first large prospective cohort study 
of  866 Japanese patients with chronic hepatitis C (CHC) 
tested whether TE can predict the future development of  
HCC[52]. During a mean follow-up of  3 years, 77 patients 
developed HCC. By multivariate analysis, together with 
age, male gender, and clinical cirrhosis, stratified TE value 
was identified as an independent risk factor for HCC 
development, with relative risks of  16.7, 20.0, 25.6 and 
45.5 for TE values of  10-15, 15-20, 20-25 and > 25 kPa, 
respectively, vs an TE value of  < 10 kPa as the reference 
and the cumulative incidence of  HCC showed a step-
wise increase according to stratified TE value (Figure 2A). 
Despite there being no histological analysis in relation to 
TE values and inclusion of  patients with high alanine ami-
notransferase (ALT) levels [> 5× upper limit of  normal 
(ULN)] both of  which can attenuate the accuracy of  TE, 
this study confirmed that severity of  liver fibrosis, reflect-
ed by higher TE values, was closely associated with higher 
kPa (HR, 12.446; P < 0.001) showed independently higher 
risks than patients with TE value < 13 kPa.
HCC 
Another promising area for the application of  TE, other 
than portal hypertension-related decompensation events, 
is the prediction of  HCC development. Unless HCC is 
diagnosed at an early stage, a poor prognosis is expected 
due to the limited treatment options[47-51]. Thus, early 
prediction of  HCC development is of  great importance, 
especially in high-risk patients. Among traditional risk 
factors, advanced liver fibrosis and cirrhosis is known 
to have a close association with risk of  HCC develop-
ment[47]. Thus, assessment of  the severity of  liver fibrosis 
at a given time point with subsequent monitoring of  liver 
fibrosis progression by serial check-up is essential for ef-
fective and optimized surveillance strategies for the early 
detection of  HCC[3].
Recently, several Asian studies have investigated the 
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Figure 2  Cumulative incidence of hepatocellular carcinoma development based on stratified transient elastography values in patients with chronic hepati-
tis C (A, n = 866) and those with chronic hepatitis B (B, n = 1130). The cumulative incidences increased significantly in association with higher TE values (log-rank 
test, all P < 0.001). In particular, the overall incidence of HCC differed significantly among the four groups (C) (both initial and follow-up TE values ≤ 13 kPa (group 1), 
initial TE value > 13 kPa and follow-up TE value ≤ 13 kPa (group 2), initial TE value ≤ 13 kPa and follow-up TE value > 13 kPa (group 3), and both initial and follow-
up TE values > 13 kPa (group 4) according to changing patterns of TE value during follow-up (P < 0.001; Figure 2C). A: Cited from Masuzaki et al[52]; B and C: Cited 
from Jung et al[53]. HCC: Hepatocellular carcinoma; TE: Transient elastography; LSM: Liver stiffness measurement. 
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risk of  HCC development and suggested a clinical role for 
TE in a longitudinal setting using HCC development as a 
solid clinical endpoint. Interestingly, in this study, even pa-
tients with not so high level of  TE (10-15 kPa) were still 
more subject to HCC development with an adjusted HR 
of  16.7, compared to those with a TE value < 10 kPa.
Another large Korean cohort study with 1130 patients 
with chronic hepatitis B (CHB) also confirmed the lon-
gitudinal role of  TE on HCC development[53]. Together 
with age, male gender, heavy alcohol consumption, lower 
serum albumin, and HBeAg positivity, stratified TE value 
was identified as an independent risk factor for HCC 
development, with relative risks of  3.07, 4.68, 5.55 and 
6.60 for liver stiffness measurement (LSM) values of  8-13, 
13-18, 18-23 and > 23 kPa, respectively, when compared 
with a LSM value of  < 8 kPa as a reference (Figure 2B). 
In contrast to the Japanese study[52], several additional 
issues were further analyzed in this Korean study. First, 
when the diagnosis of  cirrhosis showed discordant results 
between TE-based and clinical-based criteria, patients 
with cirrhosis based on TE were at a higher risk of  HCC 
development than those with cirrhosis based on clinical 
criteria, indicating the superiority of  TE for diagnosis of  
compensated liver cirrhosis. Second, patients with TE 
values below the cutoff  level for cirrhosis, 8-13 kPa, had 
a higher relative risk of  HCC development than those 
with LSM values < 8 kPa. Although this finding should 
be validated in large prospective studies, the issue of  ex-
pansion of  the high-risk group for HCC surveillance to 
include those with significant fibrosis was raised by this 
study. Furthermore, when patients with available follow-
up TE values were analyzed, the risk of  HCC develop-
ment changed according to the pattern of  the changes 
in TE values, suggesting a potential role for serial mea-
surements of  TE as a dynamic monitoring tool for risk 
estimation of  HCC development (Figure 2C). However, 
other confounding factors including lack of  histological 
information, insensitive HBV DNA tests, and heteroge-
neity in antiviral treatment should be noted when inter-
preting these results. Recently, Chon et al[56] compared the 
performance of  various noninvasive fibrosis prediction 
methods [aspartate aminotransferase-to-platelet ratio in-
dex (ARRI), age-spleen-to-platelet ratio index (ASPRI), 
TE, LSPS, P2/MS and FIB-4] for prediction of  HCC de-
velopment in patients with CHB and concluded that TE 
and LSPS showed the best performance (AUROC = 0.789 
and 0.788, respectively). Using multivariate analyses, TE 
and LSPS were identified as independent predictors of  
HCC development.
In another study[54] from Hong Kong, which followed 
up 528 patients with HBeAg negative CHB for a median 
length of  35 mo and identified seven patients with HCC 
development, the cumulative incidence of  HCC was 
higher in patients with TE values ≥ 10 kPa than those 
with TE values < 10 kPa (9% vs 0%, respectively; P < 
0.001), and the cumulative liver-related mortality was also 
higher in patients with TE values < 10 kPa compared 
with those with TE values ≥ 10 kPa (4% vs 0%, respec-
tively; P < 0.001). By multivariate analysis, only TE value 
was significantly associated with HCC development and 
liver-related mortality.
Similarly, Kim et al[55] investigated the prognostic role 
of  TE in predicting the development of  overall liver-
related events (LREs), defined as development of  HCC, 
hepatic decompensation, or liver-related mortality, among 
128 patients with CHB showing histologically advanced 
liver fibrosis (≥ F3) and high viral loads (HBV DNA ≥ 
2000 IU/mL) before starting nucleos(t)ide analogs. When 
the study population was stratified into two groups us-
ing the optimal cutoff  value (19 kPa), patients with TE 
values > 19 kPa were at significantly greater risk for LRE 
development than those with TE values ≤ 19 kPa (HR, 
7.176; P = 0.001). Moreover, the incidence of  LREs was 
similar in patients with F3 and F4 (22.2% vs 13.6%; P = 
0.472); however, it differed significantly between patients 
with TE values ≤ 19 kPa and those with TE values > 19 
kPa (6.9% vs 44.4%; P < 0.001), indicating the superior 
performance of  TE to that of  histology in prediction of  
LRE development. 
Apart from predicting HCC development, the appli-
cation of  TE was validated in a study by Vergniol et al[57], 
in which 1457 patients with CHC were followed up; 5-year 
survival outcomes worsened as TE values increased. The 
prognostic values of  TE were demonstrated to be statis-
tically significant (P < 0.0001) after adjustment for other 
important factors, including treatment response, patient 
age, and estimates of  necroinflammatory grade. For ex-
ample, the 5-year overall survival was 96% in patients 
with TE value < 9.5 kPa, and 47% in patients with TE 
value > 40 kPa.
Overall, TE has shown the potential for a clinical role 
in predicting the development of  portal hypertension-
related hepatic decompensation and/or HCC and, in part, 
demonstrated superior performance to histology and other 
noninvasive tools[41,58-63]. This is most likely due to the wider 
dynamic range of  TE values in the evaluation of  liver cir-
rhosis. In fact, as the stage of  ‘‘cirrhosis’’ has to date been 
defined by histopathological evidence of  one or two quali-
tative categories (METAVIR stage F4 or ISHAK S5-S6), or 
more generally by the presence of  so-called ‘‘regenerative’’ 
or ‘‘cirrhotic nodules’’, an interval scale cannot be used in 
this setting[64-66]. However, the degree of  liver fibrosis may 
vary widely among patients in this category, and the risk of  
hepatic decompensation and HCC may not be uniform. 
Thus, in this regard, because TE value, expressed in kPa as 
a continuous variable, has a wide dynamic range within the 
cirrhotic stage from the cutoff  level from non-cirrhosis 
(15-17 kPa) to the upper measurement limit of  present de-
vices (75 kPa), it would seem to be a more reasonable tool 
for detailed prognostication.
UTILITY OF TE IN THE SURGICAL 
SETTING
Because TE values show significant correlations with 
portal hypertension and HCC development, prediction 
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of  postoperative short-term outcomes, such as hepatic 
insufficiency, and long-term outcomes, such as recurrence 
or liver-related death using TE has been tested in several 
pilot studies[67-69]. Although further studies are required to 
validate these results, TE may facilitate stratification of  
patients undergoing curative resection according to dif-
ferent prognoses.
In the first place, Kim et al[67] investigated whether 
preoperative TE values could predict the development of  
postoperative hepatic insufficiency after curative resec-
tion of  HCC. In this study, multivariate analyses revealed 
that a TE value > 25.6 kPa was the only predictor of  
postoperative insufficiency. The AUROC of  25.6 kPa 
was higher than that of  indocyanine green R15, which is 
a popular method for assessment of  preoperative func-
tional reserve liver function (0.824 vs 0.620, respectively). 
Similar results were obtained in a subsequent investiga-
tion by the same group[68]. In this study, the performance 
of  TE was superior to that of  diffusion-weighted mag-
netic resonance imaging, which has also been shown to 
be a noninvasive fibrosis prediction tool for the assess-
ment of  liver fibrosis and the prediction of  postoperative 
hepatic insufficiency.
Another issue is prediction of  HCC recurrence after 
curative resection, that is, de novo recurrence in the back-
ground liver with fibrotic burden, using preoperative TE. 
In an analysis of  133 patients who underwent preopera-
tive TE and curative resection (HCC recurred in 62 pa-
tients), TE was selected as an independent predictor of  
recurrence, whereas histological fibrosis status was not[69]. 
In the study, patients with preoperative TE values > 13.4 
kPa were at a greater risk of  recurrence, with an HR of  
1.925 (P = 0.010). More specifically, when recurrence was 
stratified into early (< 2 years) and late (≥ 2 years), TE 
values were significantly related to late recurrence, thus 
supporting the hypothesis. These results suggest that pre-
operative TE could reveal the potential influence of  liver 
fibrosis on recurrence and explain multicentric carcino-
genesis in a fibrotic liver. However, more data are needed 
to clarify this issue.
ROLE OF TE IN MONITORING FIBROTIC 
BURDEN DURING ANTIVIRAL THERAPY
Recently, the concept of  “cirrhosis” has changed from 
static and uncompromisingly progressive to rather 
dynamic and bidirectional, especially when treatment 
against the causative agent of  tissue damage (i.e., antiviral 
agents against CHB or CHC and antifibrotic agents) can 
be introduced successfully at this stage of  the disease. 
The ideal approach to evaluate histological outcomes du-
ring antiviral therapy, such as fibrosis regression and ne-
croinflammation stabilization, is serial LB examinations. 
However, this is impractical, primarily due to the inherent 
invasiveness of  LB. Instead, because of  the ease, safety, 
and rapidity of  TE, it may be useful for monitoring the 
dynamic changes in liver fibrosis during antiviral or anti-
fibrotic treatment. Indeed, several studies have reported 
the clinical usefulness of  TE for monitoring potential 
fibrosis regression during antiviral treatment in patients 
with CHC and CHB[57,70-77].
Kim et al[71] analyzed 41 patients with CHB who re-
ceived antiviral treatment using nucleos(t)ide analogs. 
To prevent the confounding effect of  high ALT, pa-
tients with high ALT levels more than 2× ULN, were 
excluded. Although ALT levels did not show a statisti-
cally significant change during the first 12 or 24 mo of  
antiviral treatment, TE values decreased significantly, 
indicating potential fibrosis regression due to prolonged 
antiviral treatment. Indeed, fibrosis regression and stabi-
lization of  necroinflammation was noted in two patients 
with available paired LBs. Enomoto et al[70] reported the 
changes in LSM values during the first 12 mo of  enteca-
vir treatment in 20 patients. Median TE values decreased 
significantly from 11.2 to 7.8 kPa after 12 mo of  treat-
ment, and serum fibrosis markers, such as PIIINP and 
type Ⅳ collagen 7S domain, also decreased significantly. 
In one patient with available paired LBs, histological fi-
brosis regression and stabilization of  necroinflammation 
were noted. Although these studies suggest a role for TE 
for monitoring fibrosis regression due to prolonged an-
tiviral treatment, the short duration of  observation and 
small sample sizes with paired biopsies are major limita-
tions of  these studies.
Recently, data regarding a longer antiviral treatment 
duration (more than 3 years) have become available[72-74,78]. 
Fung et al[72] reported a significant decline in TE values 
from baseline after subsequent ALT normalization with 
3-year treatment (n = 110, 7.8 to 6.1 kPa; P = 0.002). In 
this study, independent factors associated with a signifi-
cant decline in TE value of  ≥ 1 kPa included antiviral 
therapy and ALT levels at the follow-up time point. 
Another study by Andersen et al[78] also noted significant 
declines in TE values after a median antiviral treatment 
duration of  50.5 mo (n = 66), and concluded that pro-
longed antiviral treatment in patients with CHB resulted 
in significant declines in TE values, suggesting regression 
of  fibrosis in a majority of  patients with advanced fibro-
sis or cirrhosis.
Likewise, for patients with CHC, changes in TE va-
lues during antiviral treatment have been investigated 
in several studies. Two prospective studies by Vergniol 
et al[57] and Ogawa et al[75] demonstrated that patients 
with CHC showing sustained virological responses to 
pegylated interferon-ribavirin combination therapy had 
significantly reduced TE values at the end of  follow-up. 
Moreover, Ogawa et al[75] reported that patients with non-
sustained virological responses, but with a biochemical 
response, showed a greater reduction in TE values than 
did those with a non-biochemical response. Subsequent 
studies reported similar results, suggesting that changes 
in TE values during antiviral treatment in patients with 
CHC may represent alterations in the severity of  liver 
fibrosis[76,77]. However, it should be further confirmed 
whether the favorable changes in LSM values during or 
after antiviral treatment does have a significant influecne 
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on the long-term prognosis such as disease-specific survi-
val in patients with CHC.
Taken together, TE value seems to decrease dur-
ing and after antiviral therapy. However, without paired 
histological results through repeated LB, whether the 
reduction in TE values is closely correlated with regres-
sion of  liver fibrosis or improvement in necroinflamma-
tory scores remains unclear. To clarify this, Lim et al[73] 
investigated patterns of  TE values among patients who 
were treated with entecavir. In all subjects, the median 
TE value at baseline was 15.1 (range, 5.6-75.0) kPa and 
decreased significantly, to 8.8 (range, 3.0-33.8) kPa after 
12 mo of  therapy, and a decrease in TE values correlated 
significantly with increase in albumin, decrease in biliru-
bin, decrease in ALT level, and decrease in aspartate ami-
notransferase levels (all P < 0.05). However, among 15 
patients with available paired LBs, decreases in TE values 
were correlated significantly with improved necroinflam-
matory scores, but not with fibrosis regression. Similarly, 
Wong et al[74] insisted that the decline in absolute TE val-
ues during antiviral treatment did not reflect the change 
in histologically assessed liver fibrosis, probably due to 
the confounding influence of  ALT reduction caused by 
antiviral treatment.
However, regardless of  whether TE values during 
antiviral treatment are due to fibrosis regression, activity 
stabilization, or both, changes in TE value during antiviral 
treatment can be translated into the overall response of  
chronically diseased liver to antiviral treatment from the 
viewpoint of  its long-term clinical implications. Thus, it 
is more logical to investigate whether the decline in TE 
value can be used as a favorable predictor of  long-term 
prognosis. Encouraging results were recently published 
by Jung et al[53] suggesting that the change in TE values in 
patients with CHB showed a significant correlation with 
differential future risk of  HCC development. Additionally, 
Kim et al[79] insisted that changes in TE values were signifi-
cantly associated with the difference risk of  liver-related 
event occurrence, such as hepatic decompensation, HCC 
development, and LREs (Figure 3). This would suggest 
that the assessment of  overall background liver status us-
ing TE may be an important end-point in the manage-
ment of  CHB and prediction of  long-term outcomes. 
Further research is needed to evaluate the reproducibility 
of  such findings in independent populations.
LIMITATIONS OF TE
Although TE has demonstrated reliable diagnostic accura-
cy with excellent inter-observer and intra-observer agree-
ment, additional space-occupying tissue abnormalities, 
such as edema and inflammation, cholestasis, and conges-
tion may interfere with TE, regardless of  the degree of  
liver fibrosis, because the liver is wrapped in a distensible, 
but non-elastic, envelope (Glisson’s capsule)[80]. 
First, the extent of  histological necroinflammatory ac-
tivity has been shown to influence TE results in patients 
with viral hepatitis, resulting in an overestimation of  TE 
values that increases in parallel with the degree of  necro-
inflammatory score[81-85]. Consistent with these results, a 
risk of  overestimation of  TE values has been reported in 
cases of  ALT flares in patients with acute viral hepatitis 
or CHB[86-92]. Thus, in such subjects, TE examinations 
should be delayed until ALT levels have stabilized. In 
this regard, several studies have investigated the optimal 
period (3 to 6 mo) for restoration of  the reliability of  TE 
values in patients with acute flares[88,91,93,94]. Furthermore, 
even mild to moderate elevalation in ALT can be asso-
ciated with higher liver stiffness values, and may cause 
discrepancies between TE results and the actual underly-
ing fibrosis. Apart from necroinflammation, extrahepatic 
cholestasis[95] and congestive heart failure[96-98] may also 
contribute to the overestimation of  TE.
Additionally, the performance of  TE may be limited 
in patients with a high body mass index (BMI), narrow 
intercostal space, or ascites[9]. Although TE reproduc-
ibility has been shown to be excellent in terms of  inter-
observer and intra-observer agreement, a high BMI (> 28 
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Figure 3  Incidence of liver-related events according to changes in transient elastography values after 6 mo of antiviral therapy. The overall incidence of 
liver-related events differed significantly among the four groups using TE value cutoffs of 11.6 kPa (A) and 18.2 kPa (B) (both P < 0.0001). Adapted from Kim et al[79]. 
TE: Transient elastography; LSM: Liver stiffness measurement; LREs: Liver-related events.
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kg/m2) and waist circumference were significantly associ-
ated with TE failure[99]. These results emphasize the need 
for adequate operator training and for technological im-
provements in specific patient populations, such as those 
with non-alcoholic fatty liver disease. For this, a new TE 
probe (the XL probe) was recently introduced to lessen 
the TE failure rate in obese patients; however, its efficacy 
should be further validated[100].
CONCLUSION
Over the past decade, significant progress has been made 
in the non-invasive assessment of  liver fibrosis in patients 
with CLD. Of  the methods now available, TE appears to 
be an excellent tool for assessing liver fibrosis, particu-
larly for diagnosis of  cirrhosis, and also has prognostic 
value from a longitudinal perspective. Although TE can-
not completely obviate the need for invasive tests, such as 
LB, endoscopic examination for identification of  varices, 
or HVPG, it represents an important non-invasive tool, 
enabling more efficient and tailored management strate-
gies for patients with CLD (Table 2). We hope that other 
researchers will evaluate the usefullness of  other similar 
techniques such as the measurement of  spleen stiffness 
in comparison or in combination with TE in the future.
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